Real-world outcomes among patients with metastatic colorectal cancer treated first line with bevacizumab-awwb.

Abstract

e15581 Background: Bevacizumab-awwb (MVASI) was the first FDA-approved biosimilar to Avastin (reference product, RP). Real-world data on effectiveness and safety remain limited and may help address barriers to utilization. Methods: Adult patients who had a confirmed diagnosis of metastatic colorectal cancer (mCRC) (initial presentation on or after 1 January 2018) and initiated bevacizumab-awwb between 19 July 2019 and 30 April 2020 were identified in the ConcertAI Definitive Oncology EMR Dataset. A retrospective medical chart review was conducted to evaluate patient clinical characteristics and outcome data. The current analysis focused on the subset of patients who initiated first-line (1L) bevacizumab-awwb containing therapy (with no prior use of RP) to evaluate incidence of events of interest (EOIs) (Table) and overall survival (OS) probability using Kaplan-Meier analysis. Patients were followed from the initiation of 1L therapy until death, end of record, or end of study period (June 2021), whichever occurred first. Results: A total of 129 patients who initiated bevacizumab-awwb as 1L treatment in combination with chemotherapy were included in this analysis. Majority of patients (78.3%) were treated at clinical oncology practices in a community setting (median age: 60.5 years, 53.5% male). 34.9% of patients had non-metastatic disease (stage of I/II/III) at the initial diagnosis and 38.8% had undergone surgical resection. Median duration of available follow-up data was 10.7 (range: 0.69-22.4) months. During the study period, 100 out of 129 patients had disease progression of which 46 patients had a record of death. The Kaplan-Meier analysis showed that 12-month OS probability was 71.4% (95% CI: 61.0%-79.5%). During treatment with bevacizumab-awwb, 20 EOIs were reported in 18 patients (14.0%). Distribution of events and their management are presented in the Table. None of these EOIs resulted in death. Conclusions: Biosimilar bevacizumab-awwb appeared to be well tolerated, with observed EOIs being manageable, and 12-month OS probability of > 70% for treating patients with mCRC in the real-world setting.[Table: see text]

Evaluation of bevacizumab biosimilar on wound healing complications in patients with colorectal cancer undergoing endoscopic mucosal resection: A systematic review and meta‐analysis in anorectal medicine

“…In the 2023 study conducted by Jin et al 17 the experimental group had an average success rate of 87.6% compared with the control group's 71.4%. This represented the notable difference of 16.2%, indicating that the intervention had significant effect.…”

“…The comprehensive summary of studies that investigated treatments for mCRC, with an emphasis on bevacizumab and its biosimilars revealed that Jin et al 17 assessed the efficacy of bevacizumab‐awwb treatment in adult patients with mCRC. Their primary outcomes were thromboembolic and hemorrhagic events, but none of these resulted in fatalities.…”

“…Consistent with the current literature on biosimilars, our analysis demonstrated that the reference product, Bevacizumab, and its biosimilars have comparable efficacy and safety. Several studies, including Jin et al 17 and Saab et al 18 found that experimental groups treated with biosimilars exhibited greater efficacy than control groups. Although not all studies exhibited the same degree of disparity, there was a discernible pattern of the experimental group outperforming the control.…”

“…In addition to efficacy and safety, duration of therapeutic effectiveness was of interest. In a number of studies, including those by Jin et al 17 and Saab et al 18 the experimental groups exhibited longer durations of efficacy. However, caution is required when interpreting these results.…”